Keywords: Biota, Prolysis, MaxThera, Antibacterial, M&A

Biota acquires antibacterial assets of Prolysis and of MaxThera

Article | 12 November 2009

Print This

Australia’s Biota Holdings announced two deals this morning that will greatly expand its pipeline of potentially life-saving drugs after ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in